Market priceShare price
$19.30
+1.21% (+$0.23)
NAVAsset value per share
$20.62
as of Oct 14, 2026 · Nasdaq NAV symbol
Premium / discountPrice vs. assets
6.40% discount *
Indicative: latest price vs latest reported NAV
Distribution rate (price)Payout rate
13.68%
regular, annualised · on NAV 12.80%
Expense ratioAnnual cost
Not reported
no tagged fee table
LeverageBorrowing
Not reported
senior securities not tagged
Quote status: Market closed — last regular-session price · last trade Oct 15, 2026, 4:00 PM EDT (exchange time, ET) · retrieved Oct 15, 2026, 10:43 PM EDTRegular-session prices; extended-hours quotes are not displayed.
Full portfolio as filed on SEC Form N-PORT for the month ending Jun 30, 2026, filed Aug 28, 2026. 154 positions; weights are percent of net assets as reported. Weights sum to 100.0% — leverage, cash, derivatives and short positions mean totals need not equal 100%. This is a historical report, not a live portfolio.
Top 10 holdings
| # | Security | Type | Country | Weight | Value (USD) |
|---|---|---|---|---|---|
| 1 | uniQure NV | Equity | Netherlands | 4.19% | $57.1M |
| 2 | VeraDermics Inc | Equity | United States | 3.41% | $46.5M |
| 3 | Insmed Inc | Equity | United States | 2.80% | $38.1M |
| 4 | Argenx SE | Equity | Netherlands | 2.48% | $33.8M |
| 5 | VERADERMICS, INC. | Preferred | United States | 2.25% | $30.7M |
| 6 | Personalis Inc | Equity | United States | 2.17% | $29.5M |
| 7 | Tectonic Therapeutic Inc | Equity | United States | 1.95% | $26.5M |
| 8 | Oruka Therapeutics Inc | Equity | United States | 1.91% | $26M |
| 9 | Abbott Laboratories | Equity | United States | 1.82% | $24.9M |
| 10 | BioCryst Pharmaceuticals Inc | Equity | United States | 1.71% | $23.2M |
Asset class
| Asset class | % net assets | Value |
|---|---|---|
| Equity (common) | 88.05% | $1.2B |
| Equity (preferred) | 7.70% | $105M |
| Derivative (equity) | 2.63% | $35.8M |
| Short-term investment vehicle | 1.27% | $17.3M |
| Debt | 0.28% | $3.8M |
| ABS (other) | 0.08% | $1M |
Country (top 12)
| Country (top 12) | % net assets | Value |
|---|---|---|
| United States | 83.72% | $1.1B |
| Netherlands | 7.86% | $107M |
| Ireland | 2.76% | $37.6M |
| France | 1.47% | $20M |
| Canada | 1.38% | $18.9M |
| Cayman Islands | 1.19% | $16.2M |
| Switzerland | 0.74% | $10.1M |
| Belgium | 0.35% | $4.7M |
| Denmark | 0.33% | $4.5M |
| Singapore | 0.19% | $2.6M |
Region
| Region | % net assets | Value |
|---|---|---|
| United States | 83.72% | $1.1B |
| Developed Europe | 13.52% | $184M |
| Canada | 1.38% | $18.9M |
| Offshore domiciles | 1.19% | $16.2M |
| Asia ex-Japan | 0.19% | $2.6M |
Issuer type
| Issuer type | % net assets | Value |
|---|---|---|
| Corporate | 96.44% | $1.3B |
| Other | 2.63% | $35.8M |
| Registered fund | 0.93% | $12.6M |
Fair-value level
| Fair-value level | % net assets | Value |
|---|---|---|
| Level 1 | 93.08% | $1.3B |
| Level 3 | 6.83% | $93.1M |
| Level 2 | 0.08% | $1.1M |
Level 3 = valued with unobservable inputs (typically private or illiquid).
Long / short
| Long / short | % net assets | Value |
|---|---|---|
| Long | 97.37% | $1.3B |
| N/A | 2.63% | $35.8M |
All allocation percentages use net assets as the denominator (N-PORT convention). A position's share of invested assets may differ from its share of the whole fund including cash and leverage.
All 154 positions
| Security | Identifier | Type | Issuer | Country | Balance | Units | Value (USD) | Weight | FV level |
|---|---|---|---|---|---|---|---|---|---|
| uniQure NV | NL0010696654 | Equity | CORP | Netherlands | 1,240,256 | shares | $57.1M | 4.19% | 1 |
| VeraDermics Inc | 922967104 | Equity | CORP | United States | 378,002 | shares | $46.5M | 3.41% | 1 |
| Insmed Inc | 457669307 | Equity | CORP | United States | 357,466 | shares | $38.1M | 2.80% | 1 |
| Argenx SE | 04016X101 | Equity | CORP | Netherlands | 36,476 | shares | $33.8M | 2.48% | 1 |
| VERADERMICS, INC. | — | Preferred | CORP | United States | 249,839 | shares | $30.7M | 2.25% | 1 |
| Personalis Inc | 71535D106 | Equity | CORP | United States | 2,204,516 | shares | $29.5M | 2.17% | 1 |
| Tectonic Therapeutic Inc | 878972108 | Equity | CORP | United States | 770,940 | shares | $26.5M | 1.95% | 1 |
| Oruka Therapeutics Inc | 687604108 | Equity | CORP | United States | 273,474 | shares | $26M | 1.91% | 1 |
| Abbott Laboratories | 002824100 | Equity | CORP | United States | 273,941 | shares | $24.9M | 1.82% | 1 |
| BioCryst Pharmaceuticals Inc | 09058V103 | Equity | CORP | United States | 2,323,964 | shares | $23.2M | 1.71% | 1 |
| UnitedHealth Group Inc | 91324P102 | Equity | CORP | United States | 53,414 | shares | $22.2M | 1.63% | 1 |
| Humana Inc | 444859102 | Equity | CORP | United States | 55,623 | shares | $22.1M | 1.62% | 1 |
| Denali Therapeutics Inc | 24823R105 | Equity | CORP | United States | 857,414 | shares | $22.1M | 1.62% | 1 |
| IMMUNIC | — | Equity deriv. | OTHER | United States | 1,769,493 | shares | $21.7M | 1.59% | 1 |
| Amgen Inc | 031162100 | Equity | CORP | United States | 55,824 | shares | $20.2M | 1.48% | 1 |
| Immunovant Inc | 45258J102 | Equity | CORP | United States | 519,819 | shares | $20M | 1.47% | 1 |
| Abivax SA | 00370M103 | Equity | CORP | France | 150,132 | shares | $20M | 1.47% | 1 |
| Praxis Precision Medicines Inc | 74006W207 | Equity | CORP | United States | 59,398 | shares | $19.9M | 1.46% | 1 |
| Crinetics Pharmaceuticals Inc | 22663K107 | Equity | CORP | United States | 508,242 | shares | $19M | 1.40% | 1 |
| EyePoint Inc | 30233G209 | Equity | CORP | United States | 1,220,913 | shares | $17.5M | 1.28% | 1 |
| Medtronic PLC | IE00BTN1Y115 | Equity | CORP | Ireland | 211,663 | shares | $16.6M | 1.22% | 1 |
| Danaher Corp | 235851102 | Equity | CORP | United States | 86,804 | shares | $16.5M | 1.21% | 1 |
| Intuitive Surgical Inc | 46120E602 | Equity | CORP | United States | 41,349 | shares | $16.4M | 1.21% | 1 |
| Dyne Therapeutics Inc | 26818M108 | Equity | CORP | United States | 739,587 | shares | $16.4M | 1.21% | 1 |
| NEUROVANCE MILESTONE INTERESTrestricted | — | Equity | CORP | United States | 49,006 | shares | $16.4M | 1.21% | 3 |
| Structure Therapeutics Inc | 86366E106 | Equity | CORP | Cayman Islands | 301,239 | shares | $16.2M | 1.19% | 1 |
| Newamsterdam Pharma Co NV | NL00150012L7 | Equity | CORP | Netherlands | 476,416 | shares | $16.1M | 1.19% | 1 |
| CVS Health Corp | 126650100 | Equity | CORP | United States | 154,920 | shares | $16M | 1.18% | 1 |
| Edgewise Therapeutics Inc | 28036F105 | Equity | CORP | United States | 383,924 | shares | $15.6M | 1.15% | 1 |
| Revolution Medicines Inc | 76155X100 | Equity | CORP | United States | 83,270 | shares | $15.6M | 1.14% | 1 |
| Summit Therapeutics Inc | 86627T108 | Equity | CORP | United States | 1,062,820 | shares | $15.5M | 1.14% | 1 |
| Sarepta Therapeutics Inc | 803607100 | Equity | CORP | United States | 844,819 | shares | $15.2M | 1.11% | 1 |
| Thermo Fisher Scientific Inc | 883556102 | Equity | CORP | United States | 28,689 | shares | $14.4M | 1.06% | 1 |
| Xenon Pharmaceuticals Inc | 98420N105 | Equity | CORP | Canada | 237,877 | shares | $14.4M | 1.05% | 1 |
| IMMUNIC INC. | — | Equity deriv. | OTHER | United States | 1,049,449 | shares | $14.3M | 1.05% | 1 |
| Insulet Corp | 45784P101 | Equity | CORP | United States | 92,541 | shares | $14.1M | 1.03% | 1 |
| Boston Scientific Corp | 101137107 | Equity | CORP | United States | 324,146 | shares | $13.8M | 1.02% | 1 |
| Elevance Health Inc | 036752103 | Equity | CORP | United States | 35,082 | shares | $13.6M | 1.00% | 1 |
| Ionis Pharmaceuticals Inc | 462222100 | Equity | CORP | United States | 170,945 | shares | $13.6M | 1.00% | 1 |
| Charles River Laboratories International Inc | 159864107 | Equity | CORP | United States | 58,698 | shares | $13.3M | 0.98% | 1 |
| State Street Global Advisors | 857492706 | Short-term inv. | RF | United States | 12,638,668 | shares | $12.6M | 0.93% | 1 |
| Ideaya Biosciences Inc | 45166A102 | Equity | CORP | United States | 338,878 | shares | $12.6M | 0.93% | 1 |
| ARS Pharmaceuticals Inc | 82835W108 | Equity | CORP | United States | 1,574,583 | shares | $12.6M | 0.93% | 1 |
| NeoGenomics Inc | 64049M209 | Equity | CORP | United States | 861,891 | shares | $12.6M | 0.92% | 1 |
| Vericel Corp | 92346J108 | Equity | CORP | United States | 280,492 | shares | $12.5M | 0.92% | 1 |
| Adaptive Biotechnologies Corp | 00650F109 | Equity | CORP | United States | 574,345 | shares | $12.3M | 0.90% | 1 |
| Palvella Therapeutics Inc | 697947109 | Equity | CORP | United States | 79,433 | shares | $12.1M | 0.89% | 1 |
| CURASEN THERAPEUTICS, INC.restricted | — | Preferred | CORP | United States | 24,755,355 | shares | $12.1M | 0.89% | 3 |
| Arrowhead Pharmaceuticals Inc | 04280A100 | Equity | CORP | United States | 147,490 | shares | $12M | 0.88% | 1 |
| Vaxcyte Inc | 92243G108 | Equity | CORP | United States | 206,804 | shares | $12M | 0.88% | 1 |
| GeneDx Holdings Corp | 81663L200 | Equity | CORP | United States | 163,598 | shares | $11.2M | 0.82% | 1 |
| Jazz Pharmaceuticals PLC | IE00B4Q5ZN47 | Equity | CORP | Ireland | 46,565 | shares | $11.2M | 0.82% | 1 |
| Disc Medicine Inc | 254604101 | Equity | CORP | United States | 144,554 | shares | $10.6M | 0.78% | 1 |
| GRAIL Inc | 384747101 | Equity | CORP | United States | 151,885 | shares | $10.4M | 0.76% | 1 |
| Cogent Biosciences Inc | 19240Q201 | Equity | CORP | United States | 267,937 | shares | $10.4M | 0.76% | 1 |
| Molina Healthcare Inc | 60855R100 | Equity | CORP | United States | 44,760 | shares | $10.2M | 0.75% | 1 |
| Oculis Holding AG | CH1242303498 | Equity | CORP | Switzerland | 728,600 | shares | $10.1M | 0.74% | 1 |
| Codexis Inc | 192005106 | Equity | CORP | United States | 4,437,720 | shares | $10M | 0.74% | 1 |
| Tempus AI Inc | 88023B103 | Equity | CORP | United States | 171,015 | shares | $9.9M | 0.73% | 1 |
| HOTSPOT THERAPEUTICS, INC.restricted | — | Preferred | CORP | United States | 4,228,266 | shares | $9.7M | 0.71% | 3 |
| Arcutis Biotherapeutics Inc | 03969K108 | Equity | CORP | United States | 364,356 | shares | $9.6M | 0.70% | 1 |
| Jade Biosciences Inc | 008064206 | Equity | CORP | United States | 403,515 | shares | $9M | 0.66% | 1 |
| Sionna Therapeutics Inc | 829401108 | Equity | CORP | United States | 201,736 | shares | $8.9M | 0.65% | 1 |
| Axsome Therapeutics Inc | 05464T104 | Equity | CORP | United States | 34,782 | shares | $8.5M | 0.62% | 1 |
| Mineralys Therapeutics Inc | 603170101 | Equity | CORP | United States | 314,117 | shares | $8.5M | 0.62% | 1 |
| Amylyx Pharmaceuticals Inc | 03237H101 | Equity | CORP | United States | 451,894 | shares | $8.1M | 0.60% | 1 |
| Corbus Pharmaceuticals Holdings Inc | 21833P301 | Equity | CORP | United States | 778,031 | shares | $7.3M | 0.54% | 1 |
| Immunic Inc | 4525EP200 | Equity | CORP | United States | 473,877 | shares | $7.3M | 0.53% | 1 |
| Regeneron Pharmaceuticals Inc | 75886F107 | Equity | CORP | United States | 11,310 | shares | $7.1M | 0.52% | 1 |
| Arcus Biosciences Inc | 03969F109 | Equity | CORP | United States | 226,769 | shares | $7M | 0.51% | 1 |
| Inspire Medical Systems Inc | 457730109 | Equity | CORP | United States | 148,026 | shares | $6.6M | 0.48% | 1 |
| IQVIA Holdings Inc | 46266C105 | Equity | CORP | United States | 33,670 | shares | $6.5M | 0.48% | 1 |
| Dexcom Inc | 252131107 | Equity | CORP | United States | 94,617 | shares | $6.4M | 0.47% | 1 |
| Rhythm Pharmaceuticals Inc | 76243J105 | Equity | CORP | United States | 56,806 | shares | $6.3M | 0.46% | 1 |
| ICON PLC | IE0005711209 | Equity | CORP | Ireland | 35,763 | shares | $6.2M | 0.46% | 1 |
| LENZ Therapeutics Inc | 52635N103 | Equity | CORP | United States | 1,047,183 | shares | $5.9M | 0.44% | 1 |
| Taysha Gene Therapies Inc | 877619106 | Equity | CORP | United States | 830,500 | shares | $5.7M | 0.42% | 1 |
| Krystal Biotech Inc | 501147102 | Equity | CORP | United States | 15,104 | shares | $5.6M | 0.41% | 1 |
| Cytokinetics Inc | 23282W605 | Equity | CORP | United States | 61,822 | shares | $5.3M | 0.39% | 1 |
| THIRD ARC BIO, INCrestricted | — | Preferred | CORP | United States | 2,409,466 | shares | $5.1M | 0.37% | 3 |
| Acadia Healthcare Co Inc | 00404A109 | Equity | CORP | United States | 169,720 | shares | $5M | 0.37% | 1 |
| Waters Corp | 941848103 | Equity | CORP | United States | 13,246 | shares | $5M | 0.36% | 1 |
| McKesson Corp | 58155Q103 | Equity | CORP | United States | 6,427 | shares | $4.9M | 0.36% | 1 |
| Maze Therapeutics Inc | 578784100 | Equity | CORP | United States | 161,414 | shares | $4.8M | 0.35% | 1 |
| SpyGlass Pharma Inc | 85220G109 | Equity | CORP | United States | 214,473 | shares | $4.8M | 0.35% | 1 |
| ARBOR BIOTECHNOLOGIESrestricted | — | Preferred | CORP | United States | 909,326 | shares | $4.8M | 0.35% | 3 |
| AgomAb Therapeutics NV | 00860C102 | Equity | CORP | Belgium | 363,500 | shares | $4.7M | 0.35% | 1 |
| ELOXX PHARMACEUTICALS, INC. | — | Short-term inv. | CORP | United States | 336,398 | shares | $4.7M | 0.34% | 1 |
| Zoetis Inc | 98978V103 | Equity | CORP | United States | 62,990 | shares | $4.5M | 0.33% | 1 |
| Ascendis Pharma A/S | DK0060615755 | Equity | CORP | Denmark | 16,937 | shares | $4.5M | 0.33% | 1 |
| Definium Therapeutics Inc | 24477V105 | Equity | CORP | Canada | 95,455 | shares | $4.5M | 0.33% | 1 |
| GLYCOMINE, INC.restricted | — | Preferred | CORP | United States | 7,107,218 | shares | $4.3M | 0.31% | 3 |
| CRYSTALYS THERAPEUTICS SER Arestricted | — | Preferred | CORP | United States | 3,880,820 | shares | $3.9M | 0.29% | 3 |
| QLARIS BIO, INC.restricted | — | Preferred | CORP | United States | 4,821,319 | shares | $3.9M | 0.28% | 3 |
| Tandem Diabetes Care Inc | 875372203 | Equity | CORP | United States | 249,426 | shares | $3.8M | 0.28% | 1 |
| QUELL THERAPEUTICSrestricted | — | Preferred | CORP | United States | 1,798,941 | shares | $3.7M | 0.27% | 3 |
| Eloxx Pharmaceuticals Inc | 29014R301 | Equity | CORP | United States | 269,100 | shares | $3.7M | 0.27% | 1 |
| Allogene Therapeutics Inc | 019770106 | Equity | CORP | United States | 1,770,000 | shares | $3.7M | 0.27% | 1 |
| Alkermes PLC | IE00B56GVS15 | Equity | CORP | Ireland | 69,693 | shares | $3.7M | 0.27% | 1 |
| Assembly Biosciences Inc | 045396207 | Equity | CORP | United States | 129,708 | shares | $3.6M | 0.26% | 1 |
| Relay Therapeutics Inc | 75943R102 | Equity | CORP | United States | 185,608 | shares | $3.5M | 0.25% | 1 |
| Vertex Pharmaceuticals Inc | 92532F100 | Equity | CORP | United States | 6,786 | shares | $3.4M | 0.25% | 1 |
| ATALANTA THERAPEUTICSrestricted | — | Preferred | CORP | United States | 4,239,316 | shares | $3.3M | 0.25% | 3 |
| Mobia Medical Inc | 60705V103 | Equity | CORP | United States | 243,860 | shares | $3.3M | 0.24% | 1 |
| SKYHAWK THERAPEUTICS, INC. | — | Equity | CORP | United States | 91,681 | shares | $3.2M | 0.23% | 1 |
| ENDEAVOR BIOMEDICINES, INC.restricted | — | Preferred | CORP | United States | 657,322 | shares | $3.1M | 0.23% | 3 |
| SEISMIC THERAPEUTICS, INC.restricted | — | Preferred | CORP | United States | 647,722 | shares | $2.9M | 0.21% | 3 |
| WaVe Life Sciences Ltd | SG9999014716 | Equity | CORP | Singapore | 449,159 | shares | $2.6M | 0.19% | 1 |
| NUVIG THERAPEUTICS, INCrestricted | — | Preferred | CORP | United States | 2,445,513 | shares | $2.6M | 0.19% | 3 |
| AMOLYT MILESTONErestricted | — | Preferred | CORP | United States | 15,982 | shares | $2.5M | 0.19% | 3 |
| Sera Prognostics Inc | 81749D107 | Equity | CORP | United States | 1,378,048 | shares | $2.5M | 0.18% | 1 |
| Becton Dickinson & Co | 075887109 | Equity | CORP | United States | 16,251 | shares | $2.5M | 0.18% | 1 |
| Seaport Therapeutics Inc | 81221K108 | Equity | CORP | United States | 109,862 | shares | $2.4M | 0.18% | 1 |
| ENGRAIL THERAPEUTICS INC. SERIrestricted | — | Preferred | CORP | United States | 4,768,649 | shares | $2.3M | 0.17% | 3 |
| INCENDIA THERAPEUTICS, INC.restricted | — | Debt | CORP | United States | 2,116,600 | principal | $2.1M | 0.16% | 3 |
| INFINANT HEALTH | — | Preferred | CORP | United States | 5,954,188 | shares | $1.9M | 0.14% | 1 |
| EVOMMUNE | — | Equity | CORP | United States | 121,035 | shares | $1.6M | 0.12% | 1 |
| INVETX MILESTONE INTERESTrestricted | — | Preferred | CORP | United States | 31,195 | shares | $1.6M | 0.12% | 3 |
| Tenet Healthcare Corp | 88033G407 | Equity | CORP | United States | 8,128 | shares | $1.5M | 0.11% | 1 |
| InspireMD Inc | 45779A846 | Equity | CORP | United States | 1,743,519 | shares | $1.2M | 0.09% | 1 |
| Kailera Therapeutics Inc | 482931102 | Equity | CORP | United States | 49,509 | shares | $1.1M | 0.08% | 1 |
| ABCURO, INC.restricted | — | Preferred | CORP | United States | 532,816 | shares | $1.1M | 0.08% | 3 |
| Odyssey Therapeutics Inc | 67613T104 | Equity | CORP | United States | 57,750 | shares | $1.1M | 0.08% | 1 |
| CURASEN THERAPEUTICS CONV PNrestricted | — | ABS | CORP | United States | 1,029,195 | principal | $1M | 0.08% | 3 |
| RECODE THERAPEUTICSrestricted | — | Preferred | CORP | United States | 331,413 | shares | $1M | 0.08% | 3 |
| ENDEAVOR BIOMEDICINES INC.restricted | — | Preferred | CORP | United States | 121,377 | shares | $792K | 0.06% | 3 |
| Avalyn Pharma Inc | 05348Y105 | Equity | CORP | United States | 23,511 | shares | $774K | 0.06% | 1 |
| ABCURO INC.restricted | — | Preferred | CORP | United States | 117,926 | shares | $712K | 0.05% | 3 |
| HIBERCELL,INC. SERIES Crestricted | — | Preferred | CORP | United States | 1,529,261 | shares | $709K | 0.05% | 3 |
| HIBERCELL INC.restricted | — | Equity deriv. | OTHER | United States | 14,667,525 | shares | $680K | 0.05% | 3 |
| HIBERCELL BRIDGE NOTE | — | Debt | CORP | United States | 680,000 | principal | $680K | 0.05% | 2 |
| Hemab Therapeutics Holdings Inc | 423494103 | Equity | CORP | United States | 18,307 | shares | $672K | 0.05% | 1 |
| Incendia Therapeutics, Inc.restricted | — | Preferred | CORP | United States | 1,769,383 | shares | $642K | 0.05% | 3 |
| HIBERCELL, INC. SERIES Brestricted | — | Preferred | CORP | United States | 2,773,472 | shares | $549K | 0.04% | 3 |
| BIOTHERYX, INC. SERIES Erestricted | — | Preferred | CORP | United States | 1,295,238 | shares | $524K | 0.04% | 3 |
| AVICEDA THERAPEUTICSrestricted | — | Preferred | CORP | United States | 86,599 | shares | $499K | 0.04% | 3 |
| HIBERCELL, INC.restricted | — | Debt | CORP | United States | 439,002 | principal | $439K | 0.03% | 3 |
| OCULIS HOLDINGS AG | — | Equity | CORP | United States | 21,152 | shares | $293K | 0.02% | 1 |
| QLARIS BIO BRIDGE NOTE | — | Debt | CORP | United States | 288,298 | principal | $288K | 0.02% | 2 |
| RECODE THERAPEUTICS, INC. | — | Debt | CORP | United States | 322,741 | principal | $161K | 0.01% | 3 |
| INCENDIA BRIDGE NOTE 5/2026 | — | Debt | CORP | United States | 148,322 | principal | $148K | 0.01% | 2 |
| CONTRA CHINOOK THERAPErestricted | 169CVR016 | Equity deriv. | OTHER | United States | 91,800 | shares | $29.4K | 0.00% | 1 |
| CONTRA FUSION PHARMACErestricted | 361CVR012 | Equity deriv. | OTHER | Canada | 7,593 | shares | $10.5K | 0.00% | 3 |
| Twist Bioscience Corp | 90184D100 | Equity | CORP | United States | 2 | shares | $206 | 0.00% | 1 |
| IO LIGHT HOLDINIGS, INC.restricted | — | Preferred | CORP | United States | 421,634 | shares | $42 | 0.00% | 3 |
| PRIOTHERA LIMITEDrestricted | — | Preferred | CORP | Ireland | 346,666 | shares | $40 | 0.00% | 3 |
| Willow Laboratories Inc.restricted | — | Equity | CORP | United States | 160,000 | shares | $16 | 0.00% | 3 |
| HIBERCELL, INC. SERIES Crestricted | — | Equity deriv. | OTHER | United States | 1,529,261 | shares | $2 | 0.00% | 3 |
| Afferent Milestone Interestrestricted | — | Equity | CORP | United States | 26,208 | shares | $0 | 0.00% | 3 |
| ETHISMOS RESEARCH, INC. MILESTrestricted | — | Preferred | CORP | United States | 1,180 | shares | $0 | 0.00% | 3 |
| AMPHIVENA MILESTONE INTERESTrestricted | — | Preferred | CORP | United States | 100 | shares | $0 | 0.00% | 3 |
| Options Clearing Corp. | — | Equity deriv. | OTHER | United States | -2,000 | contracts | $-635K | -0.05% | 1 |
| Options Clearing Corp. | — | Equity deriv. | OTHER | United States | -200 | contracts | $-171K | -0.01% | 1 |
| Options Clearing Corp. | — | Equity deriv. | OTHER | United States | -300 | contracts | $-74.3K | -0.01% | 1 |
Equities show share counts; bonds and loans show principal amount. Coupon, maturity and ratings are shown where the filing discloses them. Source: SEC N-PORT via market-data vendor re-serve, position-level.
Holdings reports on file
| Report date | Filed | Positions | Σ weight | Net assets (calc.) | Coverage |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 28, 2026 | 154 | 100.0% | $1.4B | full |
| Mar 31, 2026 | May 29, 2026 | 142 | 100.0% | $1.1B | full |
| Dec 31, 2025 | Feb 27, 2026 | 138 | 100.0% | $1.2B | full |
Net assets here are calculated from position values ÷ reported weights (median across positions), not a reported figure.
CEF Explorer research page for abrdn Healthcare Investors. Figures carry their own dates and sources; a discount to NAV does not guarantee convergence or any return. This is not investment advice.